AbCellera Biologics Inc. Common Shares

ABCLNASDAQUSD
6.47 USD
0.30 (4.95%)AT CLOSE (11:59 AM EDT)
6.48
0.02 (0.29%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
6.48
0.02 (0.29%)
🔴Market: CLOSED

AbCellera Biologics Inc. Common Shares (ABCL) trades at $6.47 per share. Technicals currently rate "Neutral" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place ABCL at a fair price relative to peers.

Technical & fundamental data as of Jul 17, 2026.

Open?$6.04
High?$6.55
Low?$5.95
Prev. Close?$6.16
Volume?4.2M
Avg. Volume?7.2M
VWAP?$6.33
Rel. Volume?0.59x
Bid / Ask
Bid?$6.47 × 500
Ask?$6.50 × 900
Spread?$0.03
Midpoint?$6.48
Valuation & Ratios
Market Cap?2.0B
Shares Out?305.4M
Float?208.7M
Float %?69.7%
P/E Ratio?N/A
P/B Ratio?2.11
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Employees
562
Market Cap
1.9B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-12-11
Address
150 W 4TH AVENUE
VANCOUVER, A1 V5Y 1G6
Phone: (604) 559-9005
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)? Neutral(0/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
73
Momentum?
50
Short Sent.?
26
Piotroski F-Score?3/9Weak
Altman Z-Score?3.05Safe
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?23.27%Squeeze Risk
Short Interest?48.6M
Days to Cover?5.3
Free Float208.7M
Avg Daily Volume9.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?13.52Strong
Quick Ratio?13.52Strong
Cash Ratio?1.63Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
72
2.11CHEAP
P/S?
Peers
100
S&P
3
24.94HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-9.9CHEAP
EV/Sales?
Peers
100
S&P
3
23.97HIGH
Returns & Efficiency
ROE?
S&P
8
-15.4%WEAK
ROA?
S&P
3
-11.0%WEAK
Cash Flow & Enterprise
FCF?$-189231000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day